ArticleFrontiers in immunology2026
Case report: Double-lung transplantation for Hermansky-Pudlak syndrome-associated pulmonary fibrosis and early-stage lung cancer.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung transplantation for lung cancer remains exploratory but may benefit patients with concurrent end-stage lung disease. We present a 47-year-old Asian male with Hermansky-Pudlak syndrome-associated pulmonary fibrosis (HPS-PF), a congenital right-sided aortic arch, and a MUC5B mutation-an exceptionally rare case of multifactorial pulmonary fibrosis complicated by lung cancer. Preoperatively, he exhibited rapid functional decline. After bilateral lung transplantation, respiratory function and quality of life improved significantly, enabling a return to normal work within one month. At one-year follow-up, no tumor recurrence was observed. This case highlights potential indications for transplantation in lung cancer, the need for precise preoperative assessment, tailored postoperative therapy, and recurrence risk evaluation. It also emphasizes genetic factors in pulmonary fibrosis, suggesting gene therapy and editing as future therapeutic avenues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.